After the end of trial, we will examine if cholestyramine has a significant efficacy on reducing serum phosphate level in adult hemodialysis patients. Time of the trial will be two months (8 weeks trial period) Baseline characteristics: The following data will be collected from all patients at baseline 1. Age, sex, weight, duration of ESRD and hemodialysis comorbidities. 2. Dialysis duration, serum phosphate level, serum calcium level, iPTH, BUN, Cr (mg/d L), Albumin (mg/d L), Hb (g m%), renal function test, liver function test, blood glucose level, TG, total cholesterol level, LDL-C, HDL.C. After the end of trial, we will examine if cholestyramine has a significant efficacy on reducing serum phosphate level in adult hemodialysis patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
serum phosphate level
Timeframe: 8 weeks trial period
serum calcium level
Timeframe: 8 weeks trial period
iPTH
Timeframe: 8 weeks trial period